Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and…
An institutional-grade, numbers-driven thesis on NVO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Novo Nordisk A/S (NVO) 64/100 with a 12-month base-case forecast of $47.00 — +2.2% versus the current price of $45.98. Novo Nordisk A/S trades at $45.98 in the Healthcare sector, with a market capitalisation of $204.16B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for NVO is $47.00, implying +2.2% versus the current price. The model's 12-month scenario range runs from $42.53 (bear) to $51.23 (bull), with a base case of $44.99.
On the fundamentals, Novo Nordisk A/S shows a P/E of 11.6, trailing revenue of $309.06B, revenue growth of +6.4% YoY, a dividend yield of 3.84%. This page also tracks NVO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
NVO currently carries a TradersQuant composite score of 64/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Buy". Our 12-month price target of $47.00 implies +2.2% from $45.98. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for NVO is $47.00, about +2.2% versus the latest price of $45.98. Consensus is based on 39 analysts.
TradersQuant's 12-month model forecast for NVO is a base case of $44.99, ranging from $42.53 (bear) to $51.23 (bull), an expected return of -2.1%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for NVO over the next 12 months is $44.99 in the base case (bear $42.53, bull $51.23), versus today's price of $45.98. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for NVO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates NVO's fair value at $47.00, implying +2.2% of expected upside versus the current price.
Yes — Novo Nordisk A/S pays a dividend yielding 3.84% (about $1.77 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
